ORIC Pharmaceuticals, Inc. announced its clinical development plans for its lead programs, ORIC-944 and ORIC-114, while reporting financial results for the first quarter of 2025.

The startup is one of several that have recently raised mega rounds of financing to support programs in the clinic or entering clinical testing.

As part of the agreement, Astex has taken an equity stake in Mosaic equating to a fully-diluted ownership stake of 19% equity upfront and a further 3% dependent on clinical milestones, which will ...

Recent Clinical Data for Dubodencel (DOC1021) in Glioblastoma Drive Financing with Backing from Baylor College of Medicine and The Brain Tumor Investment Fund HOUSTON, May 30, 2025 /PRNewswire ...

SAN DIEGO, June 25, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the appointment of Jared Kelly as Chief Executive ...

Pfizer has made the decision to discontinue the clinical development program for danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist being investigated for chronic weight management.

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

Organon will discontinue its OG-6219 clinical-development program, after the investigational candidate failed to meet its primary efficacy endpoint in treating endometriosis-related pain.

"We believe Mr. Kelly's well-documented ability to prioritize clinical program development, execute successful financings, and attract the attention of large industry peers will help maximize ...

NEWARK, CA / ACCESS Newswire / June 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its ...

Oncolytics Biotech® Names New CEO To Accelerate Momentum In Immunotherapy Programs. Date. 2025-06-11 07:01:11. ... With a renewed focus and sharpened clinical development plan, ...